- Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
-
Lee S, Lee DY
- KMID: 2409795
- Ann Pediatr Endocrinol Metab.
- 2017 Mar;22(1):15-26.
- doi: 10.6065/apem.2017.22.1.15
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
-
Jung CH, Mok JO
- KMID: 2452623
- J Obes Metab Syndr.
- 2019 Mar;28(1):18-29.
- doi: 10.7570/jomes.2019.28.1.18
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
-
Min SH, Cho YM
- KMID: 2173851
- J Korean Diabetes.
- 2015 Dec;16(4):252-259.
- doi: 10.4093/jkd.2015.16.4.252
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Kim HJ
- KMID: 2408656
- J Korean Diabetes.
- 2018 Mar;19(1):35-40.
- doi: 10.4093/jkd.2018.19.1.35
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
-
Kang MY, Oh TJ, Cho YM
- KMID: 2282013
- Endocrinol Metab.
- 2015 Jun;30(2):216-220.
- doi: 10.3803/EnM.2015.30.2.216
Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that increases glucose-stimulated insulin secretion in pancreatic beta-cells. Since mitochondrial function is crucial to insulin secretion, we hypothesized that GLP-1 may increase... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
-
Jeong IK
- KMID: 2416256
- J Lipid Atheroscler.
- 2018 Jun;7(1):32-41.
- doi: 10.12997/jla.2018.7.1.32
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes.... -
- CITED
-
- Close
- SHARE
-
- Close
- Understanding the Cardiovascular Effects of Incretin
-
Yoon JS, Lee HW
- KMID: 1857497
- Diabetes Metab J.
- 2011 Oct;35(5):437-443.
- doi: 10.4093/dmj.2011.35.5.437
Cardiovascular disease (CVD), a leading cause of death in patients with diabetes mellitus, has several pathogenic mechanisms that are well established. However, the traditional hypoglycemic agents do not have proven... -
- CITED
-
- Close
- SHARE
-
- Close
- Letter: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)
-
Koh G
- KMID: 2410878
- J Obes Metab Syndr.
- 2018 Mar;27(1):71-72.
- doi: 10.7570/jomes.2018.27.1.71
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
-
Cho YM, Wideman RD, Kieffer TJ
- KMID: 2169303
- Endocrinol Metab.
- 2013 Dec;28(4):262-274.
- doi: 10.3803/EnM.2013.28.4.262
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which... -
- CITED
-
- Close
- SHARE
-
- Close
- A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
-
Sargeant J, Henson J, King JA, Yates T, Khunti K, Davies MJ
- KMID: 2458626
- Endocrinol Metab.
- 2019 Sep;34(3):247-262.
- doi: 10.3803/EnM.2019.34.3.247
Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance
-
Jung MJ, Kwon SK
- KMID: 2384252
- Endocrinol Metab.
- 2014 Dec;29(4):536-544.
- doi: 10.3803/EnM.2014.29.4.536
BACKGROUND: Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke
-
Kim S, Jeong J, Jung HS, Kim B, Kim YE, Lim DS, Kim SD, Song YS
- KMID: 2389009
- Exp Neurobiol.
- 2017 Aug;26(4):227-239.
- doi: 10.5607/en.2017.26.4.227
Glucagon like peptide-1 (GLP-1) stimulates glucose-dependent insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which block inactivation of GLP-1, are currently in clinical use for type 2 diabetes mellitus. Recently, GLP-1 has... -
- CITED
-
- Close
- SHARE
-
- Close
- Genetic Polymorphism of Glucagon-Like Peptide 1 Receptor in Korean Type 2 Diabetes Mellitus
-
Lee KW, Jiang M, Piao S, Kim EA, Hong SB, Nam MS, Kim YS, Park KS, Lee HC
- KMID: 2177802
- J Korean Diabetes Assoc.
- 2005 Jan;29(1):30-38.
BACKGROUND: Glucagon-like peptide-1 (GLP-1) is a hormone secreted by intestinal L-cells, which stimulates insulin secretion from cells. The biological action of GLP-1 is mediated by the glucagon-like peptide-1... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Kim HJ, Park SO, Ko SH, Rhee SY, Hur KY, Kim NH, Moon MK, Lee BW, Kim JH, Choi KM, on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association
- KMID: 2398081
- Diabetes Metab J.
- 2017 Dec;41(6):423-429.
- doi: 10.4093/dmj.2017.41.6.423
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
-
Oh S, Chon S, Ahn KJ, Jeong IK, Kim BJ, Kang JG
- KMID: 2281530
- Diabetes Metab J.
- 2015 Jun;39(3):177-187.
- doi: 10.4093/dmj.2015.39.3.177
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between... -
- CITED
-
- Close
- SHARE
-
- Close
- Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals
-
Ahn CH, Bae JH, Cho YM
- KMID: 2466508
- Diabetes Metab J.
- 2019 Dec;43(6):879-892.
- doi: 10.4093/dmj.2018.0202
BACKGROUND: A premeal load of protein can increase satiety and reduce energy intake. Dietary fiber also conveys metabolic benefits by modulating energy intake. We made a protein-enriched, dietary fiber-fortified bar... -
- CITED
-
- Close
- SHARE
-
- Close
- Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
-
Yu SH, Cho B, Lee Y, Kim E, Choi SH, Lim S, Yi KH, Park YJ, Park KS, Jang HC
- KMID: 2281493
- Diabetes Metab J.
- 2011 Feb;35(1):58-64.
- doi: 10.4093/dmj.2011.35.1.58
BACKGROUND: We examined the change in the levels of incretin hormone and effects of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) on insulin secretion in women with previous... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
-
Kim GS, Park JH, Won JC
- KMID: 2450509
- Endocrinol Metab.
- 2019 Jun;34(2):106-116.
- doi: 10.3803/EnM.2019.34.2.106
The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular... -
- CITED
-
- Close
- SHARE
-
- Close
- Response: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)
-
Lee JY, Jang BK, Song MK, Kim HS, Kim MK
- KMID: 2410879
- J Obes Metab Syndr.
- 2018 Mar;27(1):73-74.
- doi: 10.7570/jomes.2018.27.1.73
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Improving Effect of the Acute Administration of Dietary Fiber-Enriched Cereals on Blood Glucose Levels and Gut Hormone Secretion
-
Kim EK, Oh TJ, Kim LK, Cho YM
- KMID: 2360046
- J Korean Med Sci.
- 2016 Feb;31(2):222-230.
- doi: 10.3346/jkms.2016.31.2.222
Dietary fiber improves hyperglycemia in patients with type 2 diabetes through its physicochemical properties and possible modulation of gut hormone secretion, such as glucagon-like peptide 1 (GLP-1). We assessed the... -
- CITED
-
- Close
- SHARE
-
- Close
